NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2025.

Area of Science:

• Gynecology
• Oncology

Background:

• The National Comprehensive Cancer Network (NCCN) Guidelines for Uterine Neoplasms offer guidance on diagnosis, staging, and treatment for endometrial cancer and uterine sarcoma.
• These guidelines are regularly updated by the NCCN Cervical Uterine Panel to incorporate new data and recommendations.

Purpose of the Study:

• To summarize recent updates to the NCCN Guidelines for Uterine Neoplasms.
• To highlight the adoption of the FIGO 2023 staging system for endometrial cancer.
• To present new systemic therapy recommendations for endometrial cancer management.

Main Methods:

• The NCCN Cervical Uterine Panel convenes annually to review institutional feedback, new research, and FDA approvals.
• Deliberations focus on evaluating and updating diagnostic, staging, and treatment recommendations.
• Key updates discussed include the FIGO 2023 staging system and novel systemic therapies.

Main Results:

• The NCCN Guidelines now incorporate the FIGO 2023 staging system for endometrial cancer.
• Updated recommendations include new systemic therapy options for endometrial cancer.
• Guidance for both endometrial cancer and uterine sarcoma remains current.

Conclusions:

• The NCCN Guidelines provide current, evidence-based recommendations for uterine neoplasms.
• Adoption of the FIGO 2023 staging system and new systemic therapies enhance endometrial cancer management.
• Regular guideline updates ensure optimal patient care for uterine cancers.